Aspen director Hussain resigns; EFPIA names Novartis' Jimenez president;

@FiercePharma: Goodbye Millennium brand, hello big commercial expansion for Takeda's cancer biz. More | Follow @FiercePharma

@CarlyHFierce: #ICYMI: Amgen hopes new data can give Kyprolis a jump on rival Pomalyst. Story | Follow @CarlyHFierce

> Aspen Pharmacare director Abbas Hussain has resigned, effective next February. Report

> The European Federation of Pharmaceutical Industries and Associations (EFPIA) has named Novartis ($NVS) CEO Joe Jimenez as its new president. Report

> The U.S. Department of Health and Human Services (HHS) is offering liability protections to Ebola vaccine makers. More

> With controversy brewing over the U.K.'s Cancer Drugs Fund, access to cancer treatments could be a significant issue in next year's General Election. Report

> Pfizer ($PFE) is eyeing a relaunch for Mylotarg, pulled from the market in 2010, thanks to strong new data in acute myeloid leukemia. Report

> GlaxoSmithKline ($GSK) is changing the color of its Relvar Ellipta inhaler and its packaging from blue to yellow after respiratory health professionals and patient organizations warned that patients think the device is a "reliever" inhaler. More

> McKesson ($MCK) has launched a venture capital fund to make minority investments in a wide range of healthcare-sector companies. Report (sub. req.)

Medical Device News

@FierceMedDev: #ICYMI: Epigenomics scores Chinese marketing approval for innovative colorectal cancer test. More | Follow @FierceMedDev

@EmilyWFierce: VertiFlex faces regulatory setback for spinal implant as #FDA delays panel meeting. Story | Follow @EmilyWFierce

> GI Dynamics restructures, considers strategic options after EU shipment halt. Article

> Texas Instruments launches chip for use in medical devices, wearables. Item

> Healthcare industry groups seek compatibility standards for medical devices. News

Biotech News

@FierceBiotech: Versant wraps up an over-stuffed $305M fund with eyes on Canada. Story | Follow @FierceBiotech

@DamianFierce: Fun thing about 2014's failed takeovers is drugmakers getting stuck with bluest-ever-sky sales projections. Story | Follow @DamianFierce

> R&D returns are getting better, but not by much and not for everyone, report says. Story

> Juno preps an IPO worth up to $191M amid CAR-T fever pitch. More

> Merck shows PD-1's promise in breast cancer with positive early results. Item

Drug Delivery News

> Oramed raises funds for clinical development programs through stock sale. Story

> Unilife signs supply agreement for Depot-ject delivery system. More

> 3-D vaccine triggers immune response against cancer and infections. News

> Insys collects gastric cancer orphan designation for liposome-trapped paclitaxel. More

> NC State team creates 3-D printer for nanoparticles that offers low-cost production. Story

Diagnostics News

> British startup forges ahead with quick genome sequencing tech for rare childhood diseases. More

> Qiagen joins up with Altona to distribute Ebola diagnostic. News

> Epigenomics scores Chinese marketing approval for innovative colorectal cancer test. Report

> Eurofins Scientific gets in on specialized Dx with $140M Boston Heart purchase. Item

> Invitae scores CMS and Blue Shield of California coverage for genetic tests. Article

Pharma Marketing News

> Looking for a bright side to the Merck-Cubist merger? It's the power of the sales rep. Story

> Goodbye Millennium brand, hello big commercial expansion for Takeda's cancer biz. News

> Why spend money on awareness? A new study shows the campaigns actually work. More

> Amgen hopes new data can give Kyprolis a jump on rival Pomalyst. Story

> Novartis lays off 200 primary care reps as it preps for megablockbuster LCZ696 rollout. Article

And Finally... Alisher Usmanov, Russia's richest man, has purchased the Nobel Prize medal of American biologist James Watson at an auction and plans to return it. More

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.